ArticleBiomedicine hub
Efficacy and Safety of Pioglitazone in Improving Cognitive Function among Patients with Impaired Cognition as an Add-On Therapy: A Study Protocol.
Article in Biomedicine hub. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Management strategy to improve cognition is one of the challenges faced by clinicians. Importantly, pioglitazone, a safe and cost-effective medication, has been shown to improve memory dysfunction in both animal and some clinical studies. Thus, the aim of this study was to assess and compare the effect of pioglitazone as an add-on therapy in treating cognitive decline in patients with Parkinson's disease, stroke, and dementia. Methods: This is a randomised double blind controlled trial involving individuals with severe to mild cognitive impairment (MoCA score below 26) associated with either Parkinson's disease, stroke, or dementia. All neurological conditions were clinically diagnosed based on the standard criterions. Participants were randomised 1:1 to orally take 15 mg of pioglitazone once daily for 6 months. A total sample size of 252 participants (42 per group across six groups) was calculated to detect a mean difference of 2 points in MoCA score (SD = 3), with 80% power and 5% significance level, accounting for 15% attrition. The primary outcome measure is the change in MoCA score at 6 months. Secondary outcome measures include the assessment of clinical manifestations, cognitive performance, normal neurological markers, adverse drug reactions, and medication adherence over a follow-up period of 6 months and 12 months. Conclusion: The findings of our study are hypothesis-generating. If positive, this study will support larger multicentre trials to validate efficacy, clarify subgroup responsiveness, and inform future metabolic-targeted therapeutic strategies rather than immediate clinical guideline changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.